arrow
H

Hiromi Muramatsu

University of Pennsylvania
H指数:36
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Selective decay of interferon mRNAs controls antiviral immunity and innate memory

干扰素mRNA的选择性降解调控抗病毒免疫和固有记忆

2026-09-010
PRE
RNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I

RNA-LNP介导的在体基础编辑纠正了鸟氨酸氨甲酰转移酶缺乏症小鼠模型的疾病表型

2026-05-130
PRE
Optimal murine CD4+ T cell priming by mRNA-lipid nanoparticle vaccines requires endogenous antigen processing

通过mRNA-脂质纳米颗粒疫苗引发的最佳鼠CD4 T细胞需要内源性抗原加工

2026-01-160
OAAI
Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses

mRNA疫苗的不同组分协同作用,指导高效的生发中心反应

Cell
IF42.5
2025-12-160
PREAI
Lipid Nanoparticle Library Screen Reveals Lymphatic Endothelial Cell-Targeting Lipid Nanoparticle for Delivering Vascular Endothelial Growth Factor C mRNA after Lymphatic Injury

脂质纳米颗粒库筛选揭示一种靶向淋巴内皮细胞的脂质纳米颗粒,用于在淋巴损伤后递送血管内皮生长因子C mRNA

2025-11-010
PRE
Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice

计算设计的mRNA启动的蛋白质纳米颗粒免疫原在 mice 中诱导保护性抗体和T细胞应答

2025-10-150
PRE
mRNA-LNP vaccine encoding the Plasmodium vivax circumsporozoite protein is highly immunogenic and confers protection in mice

编码恶性疟原虫环子孢子蛋白的mRNA-LNP疫苗具有高度免疫原性,并能在小鼠中提供保护。

2025-07-300
OAAI
Efficacy test of a Mycoplasma hyorhinis mRNA-LNP vaccine candidate

Mycoplasma hyorhinis mRNA-LNP疫苗候选物的效力测试

vaccine
IF2.2
2025-07-030
PRE
Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications

通过PEG脂质比例和磷脂修饰来定制脂质纳米颗粒的佐剂性

2025-06-230
PRE
Treatment of a metabolic liver disease in mice with a transient prime editing approach

使用暂时性碱基编辑方法治疗小鼠的代谢性肝病

2025-05-200
OA
mRNA-LNP vaccine-induced CD8+T cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies
2024-06-013
OAAI
Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination
2024-03-1411
OAAI